Table 3.
Overall and subgroup meta-analyses of association between rs1801516 polymorphism and cancer susceptibility under different models
| Group | AA vs GG + GA | AA+GA vs GG | AA vs GG | GA vs GG | GG + AA vs GA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | I2 (%) | P h | OR (95% CI) | I2 (%) | P h | OR (95% CI) | I2 (%) | P h | OR (95% CI) | I2 (%) | P h | OR (95% CI) | I2 (%) | P h | |
| Overall | 0.91 (0.78, 1.07) | < 0.1 | 0.616 | 1.00 (0.90, 1.11) | 60.8 | < 0.001 | 0.89 (0.75, 1.06) | 5.8 | 0.378 | 1.01 (0.91, 1.13) | 77.14 | < 0.001 | 1.00 (0.88, 1.10) | 74.4 | < 0.001 |
| Region-specified population | |||||||||||||||
| European | 0.79 (0.65, 0.96) | < 0.1 | 0.848 | 0.94 (0.82, 1.07) | 65.6 | < 0.001 | 0.79 (0.65, 0.96) | < 0.1 | 0.677 | 0.95 (0.84, 1.08) | 61.9 | < 0.001 | 1.04 (0.92, 1.18) | 60.0 | < 0.001 |
| North American | 1.09 (0.82, 1.45) | < 0.1 | 0.566 | 1.02 (0.90, 1.15) | 43.6 | 0.077 | 1.32 (0.85, 2.06) | < 0.1 | 0.408 | 1.03 (0.80, 1.32) | 52.3 | 0.050 | 0.97 (0.76, 1.25) | 52.5 | 0.049 |
| South American | 1.07 (0.1, 11.88) | – | – | 2.15 (1.37, 3.38) | 16.6 | 0.274 | 1.24 (0.11, 13.84) | – | – | 2.19 (1.38, 3.47) | 33.2 | 0.221 | 0.46 (0.29, 0.72) | 32.7 | 0.223 |
| Asian | 7.45 (1.31, 42.46) | < 0.1 | 0.956 | 1.11 (0.79, 1.58) | < 0.1 | 0.719 | 7.40 (1.30, 42.19) | < 0.1 | 0.949 | 1.00 (0.70, 1.43) | < 0.1 | 0.592 | 1.02 (0.71, 1.46) | < 0.1 | 0.584 |
| Oceanian | 1.83 (0.55, 6.05) | – | – | 2.20 (0.87, 5.58) | – | – | – | – | – | 2.20 (0.87, 5.58) | – | – | 0.46 (0.18, 1.16) | – | – |
| Cancer type | |||||||||||||||
| Breast cancer | 0.84 (0.68, 1.04) | < 0.1 | 0.777 | 1.09 (0.86, 1.38) | 78.0 | < 0.001 | 0.76 (0.59, 0.98) | < 0.1 | 0.632 | 1.11 (0.87, 1.41) | 76.4 | < 0.001 | 0.90 (0.71, 1.13) | 75.3 | < 0.001 |
| Thyroid cancer | 0.73 (0.48, 1.11) | < 0.1 | 0.886 | 0.87 (0.71, 1.07) | 52.3 | 0.033 | 0.71 (0.47, 1.08) | < 0.1 | 0.830 | 0.89 (0.67, 1.18) | 60.6 | 0.018 | 1.11 (0.84, 1.47) | 59.1 | 0.023 |
| Cervical cancer | 2.29 (0.89, 5.91) | < 0.1 | 0.379 | 0.86 (0.63, 1.18) | < 0.1 | 0.443 | 2.13 (0.83, 5.48) | 5.8 | 0.346 | 0.79 (0.57, 1.09) | < 0.1 | 0.489 | 1.29 (0.93, 1.79) | < 0.1 | 0.494 |
| Colorectal cancer | 0.44 (0.12, 1.59) | < 0.1 | 0.953 | 1.13 (0.83, 1.54) | < 0.1 | 0.874 | 0.47 (0.13, 1.69) | < 0.1 | 0.966 | 1.20 (0.87, 1.64) | < 0.1 | 0.899 | 0.82 (0.60, 1.12) | < 0.1 | 0.903 |
| Lung cancer | 1.22 (0.35, 4.20) | 55.4 | 0.134 | 1.41 (0.97, 2.05) | – | – | 2.71 (0.69, 10.61) | – | – | 1.35 (0.92, 1.98) | – | – | 0.76 (0.52, 1.12) | – | – |
| Source of controls | |||||||||||||||
| PBC | 0.83 (0.65, 1.07) | < 0.1 | 0.858 | 0.99 (0.81, 1.21) | 70.8 | < 0.001 | 0.75 (0.55, 1.03) | < 0.1 | 0.771 | 1.03 (0.83, 1.28) | 70.8 | < 0.001 | 0.96 (0.78, 1.19) | 69.9 | < 0.001 |
| HBC | 1.04 (0.80, 1.36) | 17.2 | 0.285 | 1.02 (0.86, 1.20) | 62.5 | 0.002 | 1.06 (0.80, 1.42) | 36.2 | 0.140 | 1.03 (0.86, 1.23) | 62.2 | 0.003 | 0.98 (0.82, 1.17) | 60.8 | 0.004 |
| NR | 0.88 (0.64, 1.20) | 24.0 | 0.254 | 0.93 (0.82, 1.06) | < 0.1 | 0.827 | 0.86 (0.63, 1.18) | 26.2 | 0.238 | 0.93 (0.82, 1.07) | < 0.1 | 0.928 | 1.06 (0.93, 1.20) | < 0.1 | 0.944 |
| Matched controls | |||||||||||||||
| Yes | 0.95 (0.79, 1.14) | < 0.1 | 0.514 | 0.97 (0.84, 1.12) | 64.8 | < 0.001 | 0.93 (0.75, 1.15) | 18 | 0.238 | 0.99 (0.86, 1.14) | 62.4 | < 0.001 | 1.01 (0.88, 1.16) | 60.5 | < 0.001 |
| No | 0.82 (0.59, 1.12) | < 0.1 | 0.567 | 1.02 (0.86, 1.21) | 54.9 | 0.011 | 0.81 (0.59, 1.11) | < 0.1 | 0.565 | 1.06 (0.87, 1.29) | 58.2 | 0.008 | 0.94 (0.77, 1.14) | 57.9 | 0.008 |
| Family history | |||||||||||||||
| Yes | 0.70 (0.48, 1.00) | < 0.1 | 0.574 | 1.20 (0.85, 1.71) | 73.1 | 0.001 | 0.68 (0.47, 0.98) | < 0.1 | 0.519 | 1.25 (0.88, 1.77) | 71.2 | 0.002 | 0.80 (0.57, 1.12) | 69.9 | 0.003 |
| No | 0.98 (0.82, 1.16) | < 0.1 | 0.634 | 0.97 (0.87, 1.09) | 57.9 | < 0.001 | 0.97 (0.79, 1.18) | 5.2 | 0.39 | 0.98 (0.87, 1.11) | 57.5 | < 0.001 | 1.02 (0.90, 1.14) | 56 | < 0.001 |
| Sample size | |||||||||||||||
| < 1000 | 0.95 (0.75, 1.20) | < 0.1 | 0.601 | 0.99 (0.85, 1.15) | 56.8 | < 0.001 | 0.89 (0.67, 1.20) | 4.7 | 0.399 | 1.01 (0.85, 1.19) | 56.4 | < 0.001 | 0.99 (0.84, 1.17) | 54.9 | 0.001 |
| > 1000 | 0.89 (0.72, 1.10) | 2.0 | 0.420 | 1.01 (0.87, 1.17) | 71.6 | < 0.001 | 0.89 (0.71, 1.11) | 18.1 | 0.282 | 1.02 (0.88, 1.18) | 69.9 | 0.001 | 0.98 (0.84, 1.13) | 68.7 | 0.001 |
| HWE in controls | |||||||||||||||
| Yes | 0.87 (0.73, 1.05) | < 0.1 | 0.74 | 0.99 (0.89, 1.10) | 57.5 | < 0.001 | 0.87 (0.72, 1.05) | < 0.1 | 0.58 | 1.00 (0.89, 1.12) | 56.7 | < 0.001 | 0.99 (0.89, 1.11) | 54.9 | < 0.001 |
| No | 1.09 (0.64, 1.84) | 56.0 | 0.078 | 1.06 (0.70, 1.61) | 76.3 | 0.005 | 0.95 (0.36, 2.50) | 58.3 | 0.066 | 1.08 (0.72, 1.63) | 74.4 | 0.008 | 0.92 (0.62, 1.38) | 73.5 | 0.010 |
| NR | 1.03 (0.69, 1.52) | < 0.1 | 0.631 | 29.24 (1.71, 501.48) | – | – | – | – | – | 29.24 (1.71, 501.48) | – | – | 0.03 (0.00, 0.59) | – | – |
HBC, hospital-based case–controls; PBC, population-based case–controls; NR, not report
Ph, P value of Q test for heterogeneity
Significant ORs (95% CIs) were in bold